Change over period
From:
To:
Zoom:
- 3M
- 6M
- YTD
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Scynexis Inc
NASDAQ SCYX
Data sourced from
and
and
Download Data
Scynexis Inc Price to Earnings Ratio (P/E) on June 03, 2024: 0.74
Scynexis Inc Price to Earnings Ratio (P/E) is 0.74 on June 03, 2024, a -70.59% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.
-
Scynexis Inc 52-week high Price to Earnings Ratio (P/E) is 3.17 on June 29, 2023, which is 331.43% above the current Price to Earnings Ratio (P/E).
-
Scynexis Inc 52-week low Price to Earnings Ratio (P/E) is 0.25 on March 22, 2024, which is -66.62% below the current Price to Earnings Ratio (P/E).
-
Scynexis Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is 0.73.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: SCYX
| CEO | Dr. Marco Taglietti M.D. |
| IPO Date | May 2, 2014 |
| Location | United States |
| Headquarters | 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548 |
| Employees | 29 |
| Sector | Healthcare |
| Industry | Drug manufacturers - specialty & generic |
Description
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Key trends
Similar companies
Eagle Pharmaceuticals Inc
NA
NA
Phibro Animal Health Corporation
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email